PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis

NASDAQ:PRVA • US74276R1023

23.75 USD
-1.16 (-4.66%)
At close: Feb 27, 2026
23.75 USD
0 (0%)
After Hours: 2/27/2026, 8:27:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

PRVA gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. PRVA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PRVA shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • PRVA had positive earnings in the past year.
  • In the past year PRVA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
  • PRVA had a positive operating cash flow in each of the past 5 years.
PRVA Yearly Net Income VS EBIT VS OCF VS FCFPRVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • PRVA has a Return On Assets (1.67%) which is in line with its industry peers.
  • With a Return On Equity value of 3.11%, PRVA perfoms like the industry average, outperforming 57.43% of the companies in the same industry.
  • PRVA has a Return On Invested Capital (2.75%) which is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for PRVA is significantly below the industry average of 9.08%.
  • The 3 year average ROIC (2.17%) for PRVA is below the current ROIC(2.75%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.67%
ROE 3.11%
ROIC 2.75%
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
PRVA Yearly ROA, ROE, ROICPRVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • With a Profit Margin value of 1.08%, PRVA perfoms like the industry average, outperforming 58.42% of the companies in the same industry.
  • PRVA's Profit Margin has declined in the last couple of years.
  • The Operating Margin of PRVA (1.61%) is comparable to the rest of the industry.
  • PRVA's Operating Margin has declined in the last couple of years.
  • PRVA's Gross Margin of 9.87% is on the low side compared to the rest of the industry. PRVA is outperformed by 75.25% of its industry peers.
  • In the last couple of years the Gross Margin of PRVA has remained more or less at the same level.
Industry RankSector Rank
OM 1.61%
PM (TTM) 1.08%
GM 9.87%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
PRVA Yearly Profit, Operating, Gross MarginsPRVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PRVA is destroying value.
  • PRVA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PRVA has been increased compared to 5 years ago.
  • There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRVA Yearly Shares OutstandingPRVA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PRVA Yearly Total Debt VS Total AssetsPRVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • PRVA has an Altman-Z score of 4.55. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
  • PRVA has a Altman-Z score of 4.55. This is amongst the best in the industry. PRVA outperforms 81.19% of its industry peers.
  • PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.55
ROIC/WACC0.32
WACC8.61%
PRVA Yearly LT Debt VS Equity VS FCFPRVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.3 Liquidity

  • PRVA has a Current Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of PRVA (1.60) is better than 62.38% of its industry peers.
  • A Quick Ratio of 1.60 indicates that PRVA should not have too much problems paying its short term obligations.
  • PRVA's Quick ratio of 1.60 is fine compared to the rest of the industry. PRVA outperforms 66.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
PRVA Yearly Current Assets VS Current LiabilitesPRVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.55% over the past year.
  • PRVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -9.93% yearly.
  • The Revenue has grown by 22.26% in the past year. This is a very strong growth!
  • Measured over the past years, PRVA shows a very strong growth in Revenue. The Revenue has been growing by 21.04% on average per year.
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%

3.2 Future

  • PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.69% yearly.
  • The Revenue is expected to grow by 12.09% on average over the next years. This is quite good.
EPS Next Y89.34%
EPS Next 2Y62.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.51%
Revenue Next 2Y11.2%
Revenue Next 3Y12.31%
Revenue Next 5Y12.09%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PRVA Yearly Revenue VS EstimatesPRVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
PRVA Yearly EPS VS EstimatesPRVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 139.71, the valuation of PRVA can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of PRVA is on the same level as its industry peers.
  • PRVA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.07.
  • With a Price/Forward Earnings ratio of 73.78, PRVA can be considered very expensive at the moment.
  • PRVA's Price/Forward Earnings is on the same level as the industry average.
  • PRVA is valuated expensively when we compare the Price/Forward Earnings ratio to 28.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 139.71
Fwd PE 73.78
PRVA Price Earnings VS Forward Price EarningsPRVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PRVA indicates a slightly more expensive valuation: PRVA is more expensive than 63.37% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, PRVA is valued a bit cheaper than the industry average as 69.31% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.88
EV/EBITDA 55.31
PRVA Per share dataPRVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as PRVA's earnings are expected to grow with 62.69% in the coming years.
PEG (NY)1.56
PEG (5Y)N/A
EPS Next 2Y62.69%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PRVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRIVIA HEALTH GROUP INC

NASDAQ:PRVA (2/27/2026, 8:27:42 PM)

After market: 23.75 0 (0%)

23.75

-1.16 (-4.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners98.68%
Inst Owner Change0.49%
Ins Owners1.85%
Ins Owner Change0%
Market Cap2.92B
Revenue(TTM)2.12B
Net Income(TTM)22.92M
Analysts84.29
Price Target32.15 (35.37%)
Short Float %2.31%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.55%
Min EPS beat(2)-8.97%
Max EPS beat(2)96.08%
EPS beat(4)1
Avg EPS beat(4)-2.92%
Min EPS beat(4)-60.96%
Max EPS beat(4)96.08%
EPS beat(8)1
Avg EPS beat(8)-23.29%
EPS beat(12)3
Avg EPS beat(12)-1.19%
EPS beat(16)6
Avg EPS beat(16)61.33%
Revenue beat(2)1
Avg Revenue beat(2)5.86%
Min Revenue beat(2)-6.19%
Max Revenue beat(2)17.91%
Revenue beat(4)3
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-6.19%
Max Revenue beat(4)17.91%
Revenue beat(8)7
Avg Revenue beat(8)4.33%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)10
Avg Revenue beat(16)-7.25%
PT rev (1m)-0.08%
PT rev (3m)0.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.24%
EPS NY rev (1m)0.46%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)-3.9%
Revenue NQ rev (3m)-29.49%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-29.7%
Valuation
Industry RankSector Rank
PE 139.71
Fwd PE 73.78
P/S 1.38
P/FCF 17.88
P/OCF 17.88
P/B 3.96
P/tB 9.38
EV/EBITDA 55.31
EPS(TTM)0.17
EY0.72%
EPS(NY)0.32
Fwd EY1.36%
FCF(TTM)1.33
FCFY5.59%
OCF(TTM)1.33
OCFY5.59%
SpS17.26
BVpS5.99
TBVpS2.53
PEG (NY)1.56
PEG (5Y)N/A
Graham Number4.79
Profitability
Industry RankSector Rank
ROA 1.67%
ROE 3.11%
ROCE 4.27%
ROIC 2.75%
ROICexc 6.87%
ROICexgc N/A
OM 1.61%
PM (TTM) 1.08%
GM 9.87%
FCFM 7.7%
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
ROICexc(3y)6.14%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-16.37%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
F-Score6
Asset Turnover1.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 136.39
Cash Conversion 370.18%
Profit Quality 712.96%
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z 4.55
F-Score6
WACC8.61%
ROIC/WACC0.32
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)607.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
EPS Next Y89.34%
EPS Next 2Y62.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
Revenue Next Year13.51%
Revenue Next 2Y11.2%
Revenue Next 3Y12.31%
Revenue Next 5Y12.09%
EBIT growth 1Y101.6%
EBIT growth 3YN/A
EBIT growth 5Y6.15%
EBIT Next Year451.29%
EBIT Next 3Y93.95%
EBIT Next 5Y55.92%
FCF growth 1Y49.53%
FCF growth 3Y51.38%
FCF growth 5Y33.52%
OCF growth 1Y49.53%
OCF growth 3Y51.28%
OCF growth 5Y33.26%

PRIVIA HEALTH GROUP INC / PRVA FAQ

What is the fundamental rating for PRVA stock?

ChartMill assigns a fundamental rating of 5 / 10 to PRVA.


Can you provide the valuation status for PRIVIA HEALTH GROUP INC?

ChartMill assigns a valuation rating of 3 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.


Can you provide the profitability details for PRIVIA HEALTH GROUP INC?

PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for PRVA stock?

The Price/Earnings (PE) ratio for PRIVIA HEALTH GROUP INC (PRVA) is 139.71 and the Price/Book (PB) ratio is 3.96.


Can you provide the financial health for PRVA stock?

The financial health rating of PRIVIA HEALTH GROUP INC (PRVA) is 7 / 10.